(Q50726816)

18 March 2018

title

Everolimus alters imatinib blood partition in favour of the erythrocyte. (English)

1 reference

18 March 2018

1 reference

Hans Prenen

1

1 reference

18 March 2018

Gunther Guetens

2

1 reference

18 March 2018

Gert De Boeck

3

1 reference

18 March 2018

Martin Highley

4

1 reference

18 March 2018

Allan T van Oosterom

5

1 reference

18 March 2018

Ernst A de Bruijn

6

1 reference

18 March 2018

publication date

1 August 2006

1 reference

18 March 2018

Journal of Pharmacy and Pharmacology

published in

1 reference

18 March 2018

volume

58

1 reference

18 March 2018

issue

8

1 reference

18 March 2018

page(s)

1063-1066

1 reference

18 March 2018

The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment

cites work

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.8.0006

Human red blood cells: rheological aspects, uptake, and release of cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.8.0006

In vitro partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.8.0006

Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.8.0006

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.8.0006

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.8.0006

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.8.0006

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.8.0006

21 January 2018

Identifiers

DOI

10.1211/JPP.58.8.0006

1 reference

18 March 2018

1 reference

18 March 2018